SEC Form 4 · accession 0001179110-17-005998
HALOZYME THERAPEUTICS, INC. · HALO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Harry J Leonhardt
Officer — SVP, GC and CCO
Period of report
Apr 13, 2017
Accepted (ET)
Apr 14, 2017 · 2:03 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001159036
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Apr 13, 2017 | M | 6,875 | $0.00 | A | 20,382 | D | |
| Common StockF1 | Apr 13, 2017 | F | 2,583 | $12.81 | D | 17,799 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF2 | $0.00 | Apr 13, 2017 | M | 6,875 | D | — | — | Common Stock | 6,875 | 13,750 | D |
Explanation of responses
- F1The reported disposition of 2,583 shares represents the shares that were withheld by the Issuer as payment for minimum statutory tax withholding requirements.
- F2This transaction represents the vesting and settlement of restricted stock units in shares of common stock of the Issuer.